Valuation: Savara Inc

Market Cap 1.42B 1.22B 1.14B 1.04B 1.97B 136B 1.99B 13.45B 5.24B 68.43B 5.34B 5.23B 227B P/E 2026 *
-9.72x
P/E 2027 * -16.5x
Enterprise Value 1.42B 1.22B 1.14B 1.04B 1.97B 136B 1.99B 13.45B 5.24B 68.43B 5.34B 5.23B 227B EV / Sales 2026 *
706x
EV / Sales 2027 * 17.4x
Free-Float
97.41%
Yield 2026 *
-
Yield 2027 * -
08-24 Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution in Autoimmune Pulmonary Alveolar Proteinosis At the European Respiratory Society Congress 2026 CI
08-11 Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-23 Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing MT
06-08 Savara Inc. Announces CFO Changes CI
06-08 Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 CI
05-18 Savara Inc Announces New Exercise Capacity Data From The IMPALA-2 Phase 3 Clinical Trial Of Molgramostim Inhalation Solution In Autoimmune Pulmonary Alveolar Proteinosis CI
05-12 Savara Q1 Loss Widens MT
05-12 Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss MT
05-12 Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating MT
04-15 Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP) RE
04-15 Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application MT
04-15 Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis CI
Manager TitleAgeSince
Chief Executive Officer 56 2020-11-30
Director of Finance/CFO 57 2026-07-14
Chief Tech/Sci/R&D Officer 56 2023-11-30
Director TitleAgeSince
Director/Board Member 58 2009-01-31
Director/Board Member 77 2010-09-30
Director/Board Member 72 2013-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%-3.53%+71.28%+104.57% 69.06B
+1.74%+2.81%+55.45%+88.75% 63.06B
+1.09%+24.51%+2.86%-4.20% 28.34B
-0.07%-3.45%-6.06%+464.93% 27.07B
+7.41%+13.08%+58.57%+17.04% 25.45B
+3.98%+4.37%+39.87%-15.08% 19.69B
+1.02%+5.67%+273.94%+420.34% 19.19B
+0.10%+0.19%+12.19%+550.31% 15.95B
+3.98%+8.41%+46.83%+160.78% 13.52B
Average +2.51%+3.94%+61.66%+198.61% 31.26B
Weighted average by Cap. +2.52%+2.95%+59.35%+157.97%

Financials

2026 *2027 *
Net sales 2.02M 1.73M 1.62M 1.48M 2.79M 192M 2.82M 19.06M 7.43M 97M 7.57M 7.41M 321M 81.97M 70.22M 65.72M 60.07M 113M 7.82B 114M 775M 302M 3.94B 308M 301M 13.05B
Net income -147M -126M -118M -108M -203M -14.02B -205M -1.39B -542M -7.07B -552M -540M -23.41B -78.73M -67.44M -63.12M -57.69M -109M -7.51B -110M -744M -290M -3.79B -296M -289M -12.54B
Net Debt - -
Logo Savara Inc
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-